Robotic and clinical evaluation of upper limb motor performance in patients with Friedreich’s Ataxia: an observational study

Robotic and clinical evaluation of upper limb motor performance in patients with Friedreich’s Ataxia: an observational study. Marco Germanotta, Gessica Vasco, Maurizio Petrarca, Stefano Rossi, Sacha Carniel, Enrico Bertini, Paolo Cappa and Enrico Castelli; Journal of NeuroEngineering and Rehabilitation 2015, 12:41 doi:10.1186/s12984-015-0032-6

OPEN ACCESS, FULL TEXT PDF

First Presentation of Diabetes as Diabetic Ketoacidosis in a Case of Friedreich’s Ataxia

First Presentation of Diabetes as Diabetic Ketoacidosis in a Case of Friedreich’s Ataxia. Partha Pratim Chakraborty, Sayantan Ray, Rana Bhattacharjee, Sujoy Ghosh, Pradip Mukhopadhyay, Satinath Mukhopadhyay and Subhankar Chowdhury; Clinical Diabetes April 2015 vol. 33 no. 2 84-86, doi: 10.2337/diaclin.33.2.84

Full text

Measuring Disease Progression in Giant Axonal Neuropathy: Implications for Clinical Trial Design

Measuring Disease Progression in Giant Axonal Neuropathy: Implications for Clinical Trial Design ; Lisa A. Roth, MD, MS,
Jonathan D. Marra, MA, Nicole H. LaMarca, DNP, MSN, CPNCJ; Child Neurol May 2015 30: 741-748 doi: 10.1177/0883073814542946

As part of a natural history study of giant axonal neuropathy, we hypothesized that the Friedreich Ataxia Rating Scale and the Gross Motor Function Measure would show a significant change over 6 months ....

Positive Preclinical Proof-of-Concept Results of BB-FA in Mice Model of Friedreich’s Ataxia

Positive Preclinical Proof-of-Concept Results of BB-FA in Mice Model of Friedreich’s Ataxia. BioBlast Announced Preclinical Data and Pipeline Updates. April 14, 2015

BioBlast (NasdaqGM: ORPN) announced positive in vitro and in vivo results from a therapy for Friedreich’s ataxia based on the mitochondria-targeting platform, providing support for further clinical development.

Emerging functional cross-talk between the Keap1-Nrf2 system and mitochondria

Emerging functional cross-talk between the Keap1-Nrf2 system and mitochondria. Ken Itoh,, Peng Ye, Tomoh Matsumiya, Kunikazu Tanji, and Taku Ozaki; J Clin Biochem Nutr. 2015 March; 56(2): 91–97. doi: 10.3164/jcbn.14-134

Full text Pdf

DNA Topological and Epigenetic Regulation in Neurodevelopment and Disorders

DNA TOPOLOGICAL AND EPIGENETIC REGULATION IN NEURODEVELOPMENT AND DISORDERS . NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE, Project Number: 1K99NS091508-01, Project Leader: TEE, WEE WE, NEW YORK UNIVERSITY SCHOOL OF MEDICINE

PUBLIC HEALTH RELEVANCE: The goal of this project is to gain a mechanistic perspective on the roles of DNA topology and epigenetic regulation in neurodevelopment, and their implications in human neuropsychiatric disorders such as autism, and neurodegenerative diseases such as Freidreich's ataxia.

Differential Diagnosis of Sporadic Adult-Onset Ataxia: The Role of REM Sleep Behavior Disorder

Differential Diagnosis of Sporadic Adult-Onset Ataxia: The Role of REM Sleep Behavior Disorder. Hélio A.G. Teive, Walter O. Arruda, Adriana Moro, Mariana Moscovich, Renato P. Munhoz, Parkinsonism & Related Disorders, Available online 11 April 2015, ISSN 1353-8020, http://dx.doi.org/10.1016/j.parkreldis.2015.04.001.

Mitochondrial dynamism and heart disease: changing shape and shaping change

Mitochondrial dynamism and heart disease: changing shape and shaping change. Gerald W Dorn; EMBO Molecular Medicine
Early View, Article first published online: 10 APR 2015 DOI: 10.15252/emmm.201404575

Full Text Pdf

Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia

Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia . DUBLIN, IRELAND, Apr 10, 2015 (Marketwired via COMTEX)

The Company submitted the Investigational New Drug (IND) application for ACTIMMUNE in the treatment of FA in February 2015 and announced plans to begin a Phase 3 study in the second quarter in collaboration with the Friedreich's Ataxia Research Alliance (FARA) and a sub-set of FARA's Collaborative Clinical Research Network (CCRN) study centers in FA.

An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels

An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. Eppie M. Yiu, Geneieve Tai, Roger E. Peverill, Katherine J. Lee, Kevin D. Croft, Trevor A. Mori, Barbara Scheiber-Mojdehkar, Brigitte Sturm, Monika Praschberger, Adam P. Vogel, Gary Rance, Sarah E. M. Stephenson, Joseph P. Sarsero, Creina Stockley, Chung-Yung J. Lee, Andrew Churchyard, Marguerite V. Evans-Galea, Monique M. Ryan, Paul J. Lockhart, Louise A. Corben, Martin B. Delatycki; Journal of Neurology, April 2015 DOI 10.1007/s00415-015-7719-2